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It has been well established that lead poisoning, as deﬁned by the
CDC as blood lead levels (BLLs) at or above 5 μg/dl, can lead to
long-term neurotoxic effects in children and requires immediate
treatment.1,2 As such, the CDC has long recommended clinicians’
assess to all patients for lead exposure and test BLLs for all at-risk
patients.1 Furthermore, it is increasingly recognised that there is
no safe level of lead for children due to the irreversible lifelong
detrimental effects of lead exposure.2,3 Since the disaster of lead
contaminated drinking water in Flint, MI has been uncovered,
action has been taken to test children for lead poisoning.
However, when children are tested and results show that lead
levels are below the 5 μg/dl criteria no further follow-up is
conducted with these children, as they are deemed ‘healthy’. This
practice is problematic, given that other studies have shown that
blood lead levels, even at rates lower than the poison range can
be detrimental to a child’s health.3–5 The estimated population of
Flint is ~ 99,002, with about 27% of the residents categorised as
children under the age of 18 years.6 Therefore, more than ~ 26,730
children, of whom 60% are African Americans (N= 16,038), have
been exposed to environmental lead in the drinking water.
A key factor, which almost certainly affects the range of
susceptibility to lead poisoning, is a child’s genetic makeup.
Current models for the neurotoxic effects of lead implicate the
enzyme arylsulfatase A (ASA) as a particularly signiﬁcant target of
lead in the central nervous system (CNS).7 Reduced levels of
cellular ASA by lead has been suggested to augment the other
detrimental affects of the metal, resulting in the death or impaired
function of oligodendroglia progenitor cells (OPCs) and lead to
CNS dysfunction. Certain single-nucleotide polymorphisms (SNPs)
of the gene for ASA (ARSA) cause greatly reduced levels of the
enzyme with no obvious phenotype. One of these (Asn350Ser), ﬁrst
characterised in 1989,8 when homozygous, causes up to a 60%
reduction in the intracellular levels of the enzyme.9 The
homozygous presentation results in metachromatic leukodystro-
phy, leading to loss of developmental milestones in children and
death at a young age. Low ASA activity in individuals with a
heterozygous presentation can be identiﬁed via signs and
symptoms, and it is suggested that these symptoms may be
ampliﬁed when the individual is exposed to even low levels of
environmental lead.4 Some symptoms of this heterozygous
pseudodeﬁciency and environmental lead exposure may include:
learning disabilities; behaviour problems' high blood pressure;
tremors; seizure disorder; low sperm count and so on. This SNP is
of particular relevance to the current situation in Flint, MI because
a study conducted by one of us (J.Y.T.) and colleagues in 20024 of
107 African-American children in Detroit showed that this
population had a gene frequency of ~ 0.45 for the Asn350Ser
SNP, heterozygosity at this position often referred to as a
pseudodeﬁciency. This frequency is much higher than what is
seen in people of European ancestry (CEU= 0.14) and higher
frequency of this allele has been consistently reported in
populations of African ancestry (ASW= 0.36).10 These ﬁndings
suggest that the Flint, MI population suffering lead exposure
requires a more effective approach than simply measuring lead
levels and setting a cutoff at 5 μg/dl. The question of the
appropriate response to the interaction of genetics and lead
toxicity was recently commented on by Poretz7 who stated
‘Identiﬁcation of susceptible children for targeted concern and
treatment would help alleviate the impact of the toxicant on the
at-risk population.’ We agree strongly with this premise. Genotyp-
ing, followed by targeted intervention in Flint, of children who are
at higher risk for lead poisoning should be carried out
immediately, particularly for those who test below the poison
mark. The current cutoff for clinical intervention at 5 μg/dl is
inadequate and incorrect, especially for children who are carriers
or homozygous for the Asn350Ser SNP.
On the basis of these works, it is strongly suggested that
children in Flint be genetically tested for ASA pseudodeﬁciency
(heterozygotes) and risk assessed for neurological deﬁcits due to
long-term environmental lead exposure. Currently, this testing is
not being conducted, which means people with ASA carrier status
may experience detrimental effects at a lower exposure threshold,
will not receive much-needed treatment that would help mitigate
long-term health problems. Not treating people, particularly
children, who may be at risk of both ASA pseudodeﬁciency with
concurrent lead exposure could lead to long-term health
problems including neurological impairment, neuropsychiatric
disorders, increases in blood pressure and more. On the basis of
this hypothesis, there is no time to waste testing and caring for
lead-exposed people, particularly children, as this is an urgent
matter that further exempliﬁes the need for immediate action.
Because such a large population in Flint has been affected by
environmental lead exposure, this would be the prime sample for
examining the mechanistic biochemical pathways involved in
expression of symptoms and for changes in clinical care protocols
among an effected sample not controlled by laboratory condi-
tions. Flint offers a unique environmental factor where all of the
residents have been exposed to environmental lead in the
drinking water, which is why all children should be tested. We
believe that all children should be tested for all possible
genotypes of the ASA pseudodeﬁciency.
If these children are shown to be carriers, then the families
should be afforded the same opportunities for treatment that
children with high level of lead exposure receive (e.g., nutritional
interventions to decrease absorption, physical therapy, beha-
vioural therapy, educational assistance and so on). If these
children are not tested and treated, this is a gross missed
opportunity for nurses and other health providers to utilise
precision medicine techniques to its’ full potential to help improve
the health of people in need. Ignoring symptoms, their underlying
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causes, and deeming patients as healthy with no requirement for
follow-up goes against the premise of ‘symptom science’ detailed
by the National Institutes of Health/National Institute of Nursing
Research/ and we as health providers can and will do better. Now
is the time to use symptom science in combination with genomics
to improve lives and healthcare of an otherwise underserved
population in the United States. Families can be easily tested with
non-invasive measures such as saliva samples. The risk (cost)-
beneﬁt ratio of genotyping consenting individuals in Flint lies in
favour of such testing. Such genetic testing may well lead to
improvement of the physical, physiological and/or mental health
of those exposed to the lead contaminated drinking water. This is
an initial suggestion that requires high priority in terms of
immediate and long-term follow-up of people exposed long-term
to the environmental toxin lead.
Information gathered by using a precision approach in Flint can
be used in other metropolitan areas and the approach can be
applied to investigate variation in symptoms when large-scale
toxic exposures occur. Flint is not the ﬁrst community to
experience lead toxicity from the water supply, in the early
2000s a similar exposure occurred in Washington DC in a
predominately African-American quadrant of the city. As cities
continue to age, infrastructure deteriorates and debt burdens
increase, there remains potential for similar catastrophic events to
occur. The type of precision genetic-testing approach proposed
here can be utilised not only in Flint but also in other at-risk
communities in the United States and Globally.
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